molecular diagnosis
Urine Test | TrovaGeneAbout_Us.htmlshapeimage_1_link_0
Urine Test | TrovaGeneInvestor_Information.htmlTrovaGene | About US
Molecular DiagnosticsNews.htmlInvestor Relations
About UsContact_Us.htmlTrovaGene | About Us

TrovaGene, Inc. (TROV.PK) is a developer of next-generation molecular diagnostics products that address important health problems worldwide.

Our mission is to apply our proprietary transrenal DNA/RNA test platform to develop highly sensitive, non-invasive molecular diagnostics. Our patented technology uses simple urine specimens and can be applied to a broad range of products addressing multi-billion dollar markets. We are initially targeting medical conditions in which the standard of care requires samples that are difficult, painful, or dangerous to obtain and analyze as well as conditions for which no diagnostic tests currently exist. These targets include infectious disease detection and monitoring, cancer detection and monitoring, prenatal genetic testing, monitoring organ/cell transplants and diagnosis of CNS conditions.

» read more

Welcome to TrovaGene 

TROV.PK

TrovaGene’s revolutionary transrenal DNA & RNA molecular diagnostic technology sets out to change the way medicine is practiced, by obtaining earlier diagnosis of serious illness.

  1. Key developments

March 8, 2009

TrovaGene, Inc. announces that Dr. Andreas Braun has joined the company as its Vice President and Chief Medical Officer.

» read more

March 2, 2010

TrovaGene, Inc. (formerly Xenomics Inc.) Announces Name and Ticker Symbol Change.

» read more

December 15, 2009

Xenomics, Inc., and its Subsidiary TrovaGene, Inc., Announce Italian Patent for NPM1 Testing for AML Patients.

» read more

TechnologyTechnology.htmlshapeimage_10_link_0
R&DTrovaGene_Science.htmlshapeimage_11_link_0
TrovaGene logo

Formerly Xenomics, Inc., XNOM.PK

Technology
TechnologyContact_Us.htmlshapeimage_13_link_0
TR DNA | TrovaGene